Member Info for Brighty1

It's official the RTC test is the best according to the RNS. "All devices tested had accuracy of above 92% with the AbC-19 TM Rapid Test showing the highest accuracy at 97.3%"

For the doubters, check out this paragraph: "The AbC-19TM Rapid test confirms the presence of SARS-CoV-2 IgG neutralising antibodies to the spike protein of the COVID-19 virus in a small blood sample. These neutralizing antibodies may be produced as part of the body's immune response following COVID-19 infection or post-vaccination. They not only bind to a virus, but they bind in a manner that blocks infection".

Finally, the Chair of the UK-RTC, Chris Molly is quoted as follows "This research on the different use cases for lateral flow antibody tests is welcome. The AbC-19 TM test is an important weapon in the global fight against COVID-19. It allows us to see the neutralising IgG antibodies produced in response to infection, or after vaccination."

Just ahead of the road map announcement next week.......

Good luck all ODX investors, Brighty

It has certainly been most encouraging to note the raft of late buys that have been reported after close tonight, including many from last Friday. They certainly demonstrate supreme confidence in our company. I'm looking forward to the size of the Govt and global contracts to be announced by ODX in the coming weeks. Have a great evening and bring on those RNS' Colin and the team! Onwards and upwards. Good luck, Brighty

Chuggley, very well articulated. I'm looking forward to the news flow commencing re UK Govt and global contract gains. We are in for an exciting few months. Good luck all ODX long term investors. Brighty

Yes, it just goes to show that you should never sell too early. A lesson for all Sarem shareholders. i.e. to hold Sareum and wait for the really big pay day. Those that were calling for quick returns in the Woodford fund lost out substantially following the stratospheric rises in value of holdings by Woodford in the likes of Synairgen and Dr Owen's Kymab. Imagine if they had waited a further 12 months.....Good luck all Sareum investors, Brighty

The comment at the foot of the US Active Dosing RNS is also worth highlighting. Note the "which is progressing well" reference.
"Synairgen is also running an international 610 patient Phase III trial, which is progressing well". Good luck, Brighty

An exciting 2021 for BWNG investors following the Open Offer and the seismic shift to online by UK consumers in the last 12 months. Good to see 73p paid today. Next stop 100p a share. Then back to the old trading range of 200p - 300p a share in 12-18 months time with a dividend. Good luck, Brighty

200p looking a distinct possibility today. We all know that SNG has demonstrated that it can save lives & boosts lung defences and therefore will be able stop Coronavirus and Influenza attacking and damaging the lungs. That means in the pharma sector a takeover or licencing deal is a real possibility. I'm with Numis and The Lancet on how effective Synairgen is going to be in the near future. £8-10 is my prediction per share. Lots of news incoming. Good luck, Brighty

After February 15th we should also be hearing about "regulatory approvals in a total of 27 geographies" (quote from ODX RNS). Some of you will recall how the NCYT share price shifted quickly upwards once similar global announcements were forthcoming.

In the ODX January RNS about this opportunity Colin King stated: "We look forward to being able to update investors on the potential to open up significant commercial opportunities outside of the UK in due course." Good luck, Brighty

A quick reminder of how shares in the pharma sector have soared in the last year:
NCYT 7p to 1210p
ODX 7p to 126p
AVCT 14p – 215p
SNG 6p to 240p
HEMO 1p to 15p
PYC 1.5p to 10.5p
YGEN 7p- 24p
VAL 6p to 60p
In summary, in the pharmaceutical sector the share price rises on AIM in the past few months have been phenomenal. Fingers crossed for N4P investors. Good luck, Brighty

RollinInIt, you are quite right about SNG.
6p in January 2020.
15+p in February 2020.
40+p in March 2020.
70+p in April 2020.
200+p in July 2020.
175p today.
The same could quite easily happen here. Good luck all N4P shareholders, Brighty.

In addition to the brilliant patent news yesterday some of the other updates expected from N4P include:

* Update by the end of February / early March, according to the RNS yesterday

plus
* N4P’s research in to whether Nuvec® loaded with DNA encoding a SARS-CoV-2 antigen can generate COVID-19-specific antibodies in mice.

* N4P’s potential for Nuvec® as an oral vaccine delivery system.

* N4P’s Nuvec® data on the delivery of gene silencing cancer therapies

* N4P’s update on in vivo and in vitro tests to demonstrate that Nuvec® loaded with plasmid DNA (pDNA) and messenger RNA (mRNA) can stimulate an immune response.

* N4P’s “significant interest to multiple vaccine developers” re keeping the vaccine stable and at room temperature. i.e. Nuvec® as a delivery platform could provide the solution.

* Evotec update.

Any or some of the above would see the share price rocket. Good luck, Brighty

N4P priced at 13.2p for 8am. Good luck. Brighty

Long term investors know where this is going. 500p, at least, per share in 6 months time once the various RNS' and trading updates are announced backing up what has initially been reported today. Good luck, Brighty

It was also useful that the 2020 figures are now out in the open via the RNS today so that the news moving forward is about the future prospects of ODX not the past. This was strategically important (& good investor management by Colin) so that the share price won't be held back moving forward. Good luck, Brighty

Yes, on the basis that Kymab (co-founded by Sareum NED Michael Owen) was sold to Sanofi in January for $1.1billion plus $350 in possible milestone payments there is huge scope for 50p+ per share at least for Sareum. Just look at the M&A and licencing activity in our sector and value attached to the IP and you get a real sense of the true value here. That's what I am expecting in 2021 for Sareum. We just need the various component parts to slot in to place this year re 737, Covid, SDC 1801/02, FLT3, Lupus etc Good luck, Brighty

Look at NCYT over the last 12 months. Once the ££ numbers were confirmed the share price climbed from 77p 12 months ago today to as high as 1270p in October:
77p in Feb 2020.
140p+ in March 2020.
250p+ in April 2020.
400p+ in Sept 2020.
1200+p in Oct 2020.
1100p+ in Jan 2021.
It will take a few months (and a few RNS' and trading updates) to achieve a similar trading pattern but make no mistake with Government contracts in place as well as global opportunities from Feb 15th the upward trajectory of the ODX share price is going to be one of THE shares to hold in 2021. This is only 100p a share right now. When you also factor in the possible M&A activity in the pharma sector - the Sanofi deal announced last month for Kymab for $1.1 billion springs to mind - the ODX share price today at 100p is very very cheap indeed. Good luck all ODX shareholders, Brighty.

2p divi is what I'm expecting. Derisory but better than nothing. Good luck, Brighty

Yes, "It is also particularly important as discussions with potential collaborators continue" - CEO. This sentence and the patent confirmation says it all. Things are really hotting up for N4P investors now. Good luck, Brighty

Significant buys in RMS going through today . e.g.
11-Feb-21 08:46:18 2.80 377,916 Buy* 2.70 2.80 10.58k O
11-Feb-21 09:45:38 2.80 179,018 Buy* 2.70 2.80 5,013 O
11-Feb-21 08:33:20 2.80 400,000 Buy* 2.70 2.80 11.20k O
11-Feb-21 08:27:40 2.848 351,415 Buy* 2.70 2.80 10.01k O
11-Feb-21 08:26:27 2.875 348,139 Buy* 2.70 2.80 10.01k O
11-Feb-21 08:25:54 2.875 348,139 Buy* 2.70 2.80 10.01k O
11-Feb-21 08:25:31 2.87 348,746 Buy* 2.70 2.80 10.01k O
11-Feb-21 08:25:03 2.88 250,000 Buy* 2.70 2.80 7,200 O
11-Feb-21 08:24:25 2.88 250,000 Buy* 2.70 2.80 7,200 O
11-Feb-21 08:24:06 2.90 250,000 Buy* 2.70 2.80 7,250 O
11-Feb-21 08:24:06 2.90 250,000 Buy* 2.70 2.80 7,250 O
11-Feb-21 08:22:40 2.851 402,476 Buy* 2.70 2.80 11.47k
Good luck, Brighty

UK Government contract. This is the really exciting bit in the RNS: "we are likely to deliver substantial revenue growth compared to this financial year" - Colin King. That's what investors want to hear.
Good luck, Brighty